PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
HumanaMedicare Advantage · Prior Auth · Medicare Advantage · Gastroenterology, Infectious Disease, Internal Medicine +1 moreMedium impact

Epclusa® (sofosbuvir/velpatasvir) (Revised)

Act
by Jan 1, 2025
Effective date
Jan 1, 2025
Identified
Jun 24, 2026

Summary

Humana Medicare Advantage has updated its prior authorization policy for Epclusa (sofosbuvir/velpatasvir), a hepatitis C medication. The policy requires prior authorization for chronic hepatitis C diagnosis and approves treatment for 12 weeks based on AASLD guidelines.

Get alerts when payers change rules like this one

We check Humana and other payers every day and email you when a change matches your specialty and state.

Get Humana alertsPolicy Monitoring is free. No card required.

What to do

by Jan 1, 2025 · 4 steps
01Billing team must obtain prior authorization before prescribing Epclusa (sofosbuvir/velpatasvir) tablets or oral pellets for Medicare Advantage patients.
02Verify patient has chronic hepatitis C diagnosis documented.
03Submit requests through Humana's portal at www.humana.com/PAL.
04Claims without prior authorization will be denied.

Original notice

Epclusa® (sofosbuvir/velpatasvir) (Revised)
mcp.humana.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account